The federal rule that lets a nurse practitioner prescribe a controlled substance to someone they have only ever seen on a screen runs out at the end of December 31, 2026. It is the Drug Enforcement Administration’s fourth temporary extension of the COVID-era telemedicine flexibilities, and when it ends, the Ryan Haight Act’s in-person requirement applies again to new telehealth patients. DEA’s permanent answer, a special registration for telemedicine, has sat in White House regulatory review since August 25, 2026. With six weeks left, nothing has been published.
What ends on December 31, 2026
The rule in force is 21 CFR 1307.41, as amended by the fourth temporary extension DEA and HHS published on December 31, 2025. Its first paragraph carries its own expiry: the section "is in effect until the end of the day December 31, 2026."
Until then, a DEA-registered practitioner may prescribe Schedule II to V controlled substances by telemedicine to a patient they have never evaluated in person, as long as four conditions hold:
- The prescription is for a legitimate medical purpose, written in the usual course of professional practice.
- It comes out of a visit over an interactive telecommunications system as Medicare’s telehealth rule, 42 CFR 410.78(a)(3), defines it.
- The practitioner’s DEA registration covers the schedule of the drug prescribed.
- The prescription meets every other prescription rule in 21 CFR part 1306.
Nothing in that list names physicians. It applies to any "DEA-registered practitioner," and DEA’s own definitions file nurse practitioners under mid-level practitioners, a category that covers "nurse practitioners, nurse midwives, nurse anesthetists, clinical nurse specialists and physician assistants who are authorized to dispense controlled substances by the State in which they practice." So an FNP with a DEA registration has been able to prescribe under these flexibilities on the same federal terms as a family physician, within whatever their state allows.
In the extension notice, DEA quoted one reason the date matters. A stakeholder summarized unpublished data reviewed by Epic, Johns Hopkins and Stanford: of about 44.6 million controlled-substance prescriptions across 258 organizations in 2024, more than 7 million, roughly 16 percent, were issued without a prior in-person evaluation. DEA calls the date the flexibilities lapse the "telemedicine cliff."
Key dates for DEA telemedicine prescribing
| Date | What happened | Source |
|---|---|---|
| January 17, 2025 | DEA proposes the special registration for telemedicine and finalizes the buprenorphine telemedicine rule. | Federal Register 2025-01099 |
| March 18, 2025 | Comment period on the special registration proposal closes; more than 6,475 comments arrive. | Federal Register 2025-01099 |
| December 31, 2025 | DEA and HHS publish the fourth temporary extension; the buprenorphine rule takes effect. | Federal Register 2025-24123 |
| August 25, 2026 | OIRA receives the final special registration rule, RIN 1117-AB40, for review. | OIRA rules under review |
| December 31, 2026 | The fourth extension expires when this day ends. | 21 CFR 1307.41 |
| January 1, 2027 | Without a final rule or a fifth extension, new telehealth patients need an in-person evaluation before a controlled-substance prescription. | Federal Register 2025-24123 |
Where the permanent special registration rule stands
The Ryan Haight Act, passed in 2008, lists seven situations that count as the "practice of telemedicine" and are exempt from its in-person rule. One is a special registration that DEA is supposed to create by regulation. DEA proposed that framework on January 17, 2025, took comments through March 18, 2025, and received more than 6,475 of them.
The final version is now at the Office of Information and Regulatory Affairs, the White House office that reviews significant rules before they are published. OIRA’s list of rules under review shows RIN 1117-AB40, "Special Registrations for Telemedicine and Limited State Telemedicine Registrations," at the final rule stage, received August 25, 2026, with a statutory legal deadline. It was still on that list when we checked on November 16. A rule under OIRA review can clear in weeks or stay for months, and the list gives no expected date.
The Federal Register had nothing newer either. Its record of DEA documents mentioning telemedicine had no final special registration rule and no fifth extension as of November 16.
DEA has gone to the wire before. The third extension was published on November 19, 2024, six weeks before the second one ran out. The fourth was published on December 31, 2025, the last day of the third. Each extension notice has said it buys time for permanent rules, and so far each deadline has been met with another extension rather than the rules themselves.
What the 2025 special registration proposal would require of a prescriber
The final rule may change any of this, so read the proposal as the best guide available rather than the rule you will work under. As proposed, it created three registrations, issued on a three-year cycle on a new DEA Form 224S:
| Registration | Who could hold it | Schedules by telemedicine | Proposed fee |
|---|---|---|---|
| Telemedicine Prescribing Registration | Physicians and board-certified mid-level practitioners | III to V | $888 |
| Advanced Telemedicine Prescribing Registration | Listed specialists, and mid-levels board certified in a listed specialty | II to V | $888 |
| Telemedicine Platform Registration | Online telemedicine platforms that dispense through registered clinicians | II to V | $888 |
On top of the registration, a clinician would need a State Telemedicine Registration, issued by DEA, for every state where a patient is treated, at $50 per state for clinicians. Before writing a special registration prescription, the prescriber would have to verify the patient’s identity, check the prescription drug monitoring programs of all 50 states and any district or territory that runs its own, and send the prescription electronically through EPCS.
Schedule II carried one more limit. In any calendar month, special registration prescriptions for Schedule II drugs would have to stay under 50 percent of all the Schedule II prescriptions that clinician writes, telemedicine and in person combined. DEA’s stated aim was to keep a substantial share of those prescriptions tied to in-person evaluations.
Where a family nurse practitioner fits in the proposal
Two lines in the proposal matter most for you. First, DEA wrote that "physicians and board-certified mid-level practitioners" have a legitimate need to prescribe Schedules III to V by telemedicine. Second, it said plainly that "Mid-level practitioners are, however, required to be board-certified under this proposed framework." For an FNP that means the national certification you sit for after graduating, the FNP-BC or FNP-C exam, would be the ticket to the basic registration.
The Advanced registration, the only route to Schedule II by telemedicine, is narrower. DEA limited it to psychiatrists, hospice and palliative care physicians, physicians treating patients in long-term care facilities, pediatricians, neurologists, and "mid-level practitioners and physicians from other specialties who are board certified in the treatment of psychiatric or psychological disorders, hospice care, palliative care, pediatric care, or neurological disorders unrelated to the treatment and management of pain."
Family practice is not on that list. The proposal does not say whether a family nurse practitioner certification, which covers children as part of a lifespan population, would count as board certification in "pediatric care." Our reading is that it would not, since the pediatric NP has its own certification, but DEA never addressed the question and the final rule may answer it differently. If the proposal holds, a newly certified FNP prescribing by telehealth to new patients would be working in Schedules III to V. That range includes testosterone, benzodiazepines and buprenorphine. ADHD stimulants such as Adderall, and opioids such as oxycodone and hydrocodone, are Schedule II and would need an in-person evaluation first.
The distinction between population foci is one our guide to FNP and other NP specialties covers. It is also why a psychiatric NP and a family NP reading this same proposal come away with different answers.
What happens on January 1, 2027 if DEA does nothing
If December 31 passes with no final rule and no fifth extension, the flexibilities end and the Ryan Haight Act’s default rule applies again. That default is narrower than it sounds. DEA’s own notice explains it: once a practitioner has done "at least one in-person medical evaluation of a particular patient," the Act’s remote-prescribing requirements "no longer apply to that specific practitioner-patient relationship." The notice sets no age limit on that visit, and we read that to include a visit for something else, though DEA does not say so in terms.
So the patients who would be affected are new ones whose clinician has never seen them in person. For them, a controlled-substance prescription would need an in-person evaluation first, unless one of the Act’s other exceptions applied.
One exception is already in force and doesn’t expire. DEA’s buprenorphine final rule, whose effective date was delayed twice and finally arrived on December 31, 2025, lets a DEA-registered practitioner prescribe Schedule III to V medications approved for opioid use disorder by telemedicine, audio-only included. The practitioner first reviews the prescription drug monitoring program for the state where the patient is, then may prescribe an initial six-month supply. After that, further prescriptions need an in-person evaluation or another telemedicine pathway the law allows. A family practice that treats opioid use disorder keeps that route on January 1 whatever happens to the broader flexibilities.
Your state decides what you can prescribe before DEA decides how
A DEA registration, special or not, only follows a state’s authority. DEA registers a nurse practitioner for the schedules the state lets them prescribe, and the special registration proposal required an existing DEA registration in a state where the clinician is already permitted to prescribe. So a federal telemedicine rule can widen how you reach a patient but never what your state license lets you write.
That second question varies widely. In our state-by-state prescribing dataset, 18 of the 34 states we have read attach some limit to controlled substances, separate from any limit on the rest of the formulary. A few show the range:
| State | Whose prescribing authority | Wait and controlled-substance limit |
|---|---|---|
| Washington | Your license | None beyond board approval for Schedules II to V |
| Illinois | Yours, after a wait | On your own license after 4,000 hours and 250 CE hours. Schedule II narcotics still need an ongoing physician consultation relationship, and so does a benzodiazepine past 120 days. |
| Nevada | Yours, after a wait | On your own license after two years or 2,000 hours, for Schedule II only. Either party may rescind the interim protocol at any time. |
| Kentucky | Yours, after a wait | On your own license after four years, separately on each pad. The controlled-substance exemption is applied for rather than notified, and the physician reviews your prescribing quarterly in year one. |
| Arkansas | Needs an agreement | Schedules III to V only, plus the hydrocodone combinations reclassified to Schedule II where the agreement says so. |
| Michigan | The physician's act | Both names and both DEA numbers appear on the script, and Schedule II is capped at a 90-day supply. |
Read the table against the DEA proposal and the layers stack. An Arkansas FNP under a collaborative agreement is largely confined to Schedules III to V by state law before any telemedicine rule applies. A Michigan FNP prescribes controlled substances only as a physician’s delegated act. A Washington FNP has Schedules II to V on their own license, and the federal rule would decide which of those can travel by video. Our FNP scope of practice guide shows where each state sits overall, and the collaborative agreement explainer covers what the agreements in reduced-practice states contain.
What this means if you’re studying to be an FNP
If you are still in school, nothing about your coursework changes. What changes is the job market you graduate into. Telehealth companies that see new patients by video and prescribe controlled drugs have been running on temporary flexibilities since 2020, and the next version of those rules will decide what a nurse practitioner can do in that job.
Three things are worth doing now. First, if a telehealth role is your plan, ask employers how they handle a new patient who needs a controlled substance, and whether they expect you to hold a special registration once one exists. Second, treat board certification as a requirement rather than a formality. Under the proposal, an uncertified mid-level practitioner gets no special registration at all. Third, learn your target state’s controlled-substance rules early, because they sit underneath whatever DEA decides and they differ more from state to state than the federal rule ever will.
We will update this story when DEA publishes either a final rule or another extension.
Frequently asked questions
What is the Ryan Haight Act?
Can a nurse practitioner prescribe controlled substances by telehealth right now?
What happens to existing telehealth patients after December 31, 2026?
Would an FNP qualify for DEA’s special registration?
Is the special registration rule final?
Sources
- DEA and HHS, Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, Federal Register 2025-24123 (primary source), read November 16, 2026.
- DEA, Special Registrations for Telemedicine and Limited State Telemedicine Registrations (proposed rule), Federal Register 2025-01099 (primary source), read November 16, 2026.
- eCFR, 21 CFR 1307.41, temporary extension of COVID-19 telemedicine flexibilities (primary source), read November 16, 2026.
- eCFR, 21 CFR 1300.01, definition of mid-level practitioner (primary source), read November 16, 2026.
- OIRA, regulatory actions under EO 12866 review (RIN 1117-AB40) (primary source), read November 16, 2026.
- DEA and HHS, Expansion of Buprenorphine Treatment via Telemedicine Encounter, Federal Register 2025-01049 (primary source), read November 16, 2026.
- DEA and HHS, delay of effective date for the buprenorphine and VA telemedicine rules, Federal Register 2025-05007 (primary source), read November 16, 2026.